January JAAD: Deucravacitnib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week randomized, double-blinded, placebo-controlled hase 3 POETYK PSO-1 trial

As a subscriber to Dialogues in Dermatology premium channel, you will receive new podcasts weekly and can earn CME credit. Listen each week as dermatologists discuss clinical treatments and the latest in dermatology. Dialogues in Dermatology is brought to you by the American Academy of Dermatology.

Share January JAAD: Deucravacitnib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week randomized, double-blinded, placebo-controlled hase 3 POETYK PSO-1 trial

Sign up to save your podcasts

January JAAD: Deucravacitnib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week randomized, double-blinded, placebo-controlled hase 3 POETYK PSO-1 trial

January JAAD: Deucravacitnib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week randomized, double-blinded, placebo-controlled hase 3 POETYK PSO-1 trial

More shows like AAD's Dialogues in Dermatology

JAMA Clinical Reviews

Hidden Brain

Pod Save America

White Coat Investor Podcast

JAMA Dermatology Author Interviews

Learn Skin with Dr. Raja and Dr. Hadar

The Grenz Zone

Dermasphere - The Dermatology Podcast

SmartLess

The Ezra Klein Show

Derms and Conditions

We Can Do Hard Things

Cutaneous Miscellaneous: The Dermatology Residents Podcast

The Practical Dermatology Podcast

Skin Deep MDs with Dr. Mamina Turegano, Dr. Lindsey Zubritsky and Dr. Jenny Liu